{"title":"睾酮治疗对伴有2型糖尿病和功能性性腺功能减退的肥胖男性骨转换标志物的影响。","authors":"Kristina Groti Antonič","doi":"10.1080/13685538.2022.2134338","DOIUrl":null,"url":null,"abstract":"<p><strong>Methods: </strong>Fifty-five obese males with type 2 diabetes mellitus and functional hypogonadism participated in a 2-year, double-blind, placebo-controlled study of testosterone undecanoate (TU). Bone turnover markers C-telopeptide of type I collagen (CTX) and procollagen I N-terminal propeptide (PINP) were assessed at baseline, 12 and 24 months. Bone mineral density (BMD) changes were evaluated after 24 months using dual-energy X-ray absorptiometry. Group T (<i>n</i> = 28) received TU both years. Group P (<i>n</i> = 27) received placebo first year and TU second year.</p><p><strong>Results: </strong>CTX decreased in group P from 1055 (676-1344) to 453 (365-665) pmol/L (<i>p</i> < 0.001) and from 897 (679-1506) to 523 (364-835) pmol/L (<i>p</i> < 0.001) in T. PINP decreased by 4.30 ± 8.05 μg/L in group P (<i>p</i> = 0.030) and 4.64 ± 8.86 μg/L in T (<i>p</i> < 0.023) after first year of therapy. No femoral neck BMD changes were observed in 32 patients from both groups (<i>n</i> = 16 per group). Lumbar spine BMD increased (by 0.075 ± 0.114 g/cm<sup>2</sup>; <i>p</i> = 0.019) in group T following two years of treatment.</p><p><strong>Conclusions: </strong>We observed decreased CTX, decreased PINP and increased lumbar spine BMD after two years of testosterone treatment.</p><p><strong>Clinical trials: </strong>NCT03792321; retrospectively registered trial on 4 January 2019.</p>","PeriodicalId":2,"journal":{"name":"ACS Applied Bio Materials","volume":null,"pages":null},"PeriodicalIF":4.6000,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"3","resultStr":"{\"title\":\"Impact of testosterone therapy on bone turnover markers in obese males with type 2 diabetes and functional hypogonadism.\",\"authors\":\"Kristina Groti Antonič\",\"doi\":\"10.1080/13685538.2022.2134338\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Methods: </strong>Fifty-five obese males with type 2 diabetes mellitus and functional hypogonadism participated in a 2-year, double-blind, placebo-controlled study of testosterone undecanoate (TU). Bone turnover markers C-telopeptide of type I collagen (CTX) and procollagen I N-terminal propeptide (PINP) were assessed at baseline, 12 and 24 months. Bone mineral density (BMD) changes were evaluated after 24 months using dual-energy X-ray absorptiometry. Group T (<i>n</i> = 28) received TU both years. Group P (<i>n</i> = 27) received placebo first year and TU second year.</p><p><strong>Results: </strong>CTX decreased in group P from 1055 (676-1344) to 453 (365-665) pmol/L (<i>p</i> < 0.001) and from 897 (679-1506) to 523 (364-835) pmol/L (<i>p</i> < 0.001) in T. PINP decreased by 4.30 ± 8.05 μg/L in group P (<i>p</i> = 0.030) and 4.64 ± 8.86 μg/L in T (<i>p</i> < 0.023) after first year of therapy. No femoral neck BMD changes were observed in 32 patients from both groups (<i>n</i> = 16 per group). Lumbar spine BMD increased (by 0.075 ± 0.114 g/cm<sup>2</sup>; <i>p</i> = 0.019) in group T following two years of treatment.</p><p><strong>Conclusions: </strong>We observed decreased CTX, decreased PINP and increased lumbar spine BMD after two years of testosterone treatment.</p><p><strong>Clinical trials: </strong>NCT03792321; retrospectively registered trial on 4 January 2019.</p>\",\"PeriodicalId\":2,\"journal\":{\"name\":\"ACS Applied Bio Materials\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":4.6000,\"publicationDate\":\"2022-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"3\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"ACS Applied Bio Materials\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/13685538.2022.2134338\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"MATERIALS SCIENCE, BIOMATERIALS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"ACS Applied Bio Materials","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/13685538.2022.2134338","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MATERIALS SCIENCE, BIOMATERIALS","Score":null,"Total":0}
引用次数: 3
摘要
方法:55名患有2型糖尿病和功能性性腺功能减退症的肥胖男性参与了一项为期2年的双盲、安慰剂对照研究。在基线、12和24个月时评估骨转换标志物I型胶原c端肽(CTX)和I型前胶原n端前肽(PINP)。24个月后采用双能x线骨密度仪评估骨密度变化。T组(n = 28)每年均接受TU治疗。P组(n = 27)第一年使用安慰剂，第二年使用TU。结果:P组CTX由1055(676-1344)降至453 (365-665)pmol/L (P P = 0.030)， T组为4.64±8.86 μg/L (P n = 16 /组)。腰椎骨密度增高(0.075±0.114 g/cm2;p = 0.019)。结论:经过两年的睾酮治疗，我们观察到CTX降低，PINP降低，腰椎骨密度增加。临床试验:NCT03792321;回顾性注册试验于2019年1月4日进行。
Impact of testosterone therapy on bone turnover markers in obese males with type 2 diabetes and functional hypogonadism.
Methods: Fifty-five obese males with type 2 diabetes mellitus and functional hypogonadism participated in a 2-year, double-blind, placebo-controlled study of testosterone undecanoate (TU). Bone turnover markers C-telopeptide of type I collagen (CTX) and procollagen I N-terminal propeptide (PINP) were assessed at baseline, 12 and 24 months. Bone mineral density (BMD) changes were evaluated after 24 months using dual-energy X-ray absorptiometry. Group T (n = 28) received TU both years. Group P (n = 27) received placebo first year and TU second year.
Results: CTX decreased in group P from 1055 (676-1344) to 453 (365-665) pmol/L (p < 0.001) and from 897 (679-1506) to 523 (364-835) pmol/L (p < 0.001) in T. PINP decreased by 4.30 ± 8.05 μg/L in group P (p = 0.030) and 4.64 ± 8.86 μg/L in T (p < 0.023) after first year of therapy. No femoral neck BMD changes were observed in 32 patients from both groups (n = 16 per group). Lumbar spine BMD increased (by 0.075 ± 0.114 g/cm2; p = 0.019) in group T following two years of treatment.
Conclusions: We observed decreased CTX, decreased PINP and increased lumbar spine BMD after two years of testosterone treatment.
Clinical trials: NCT03792321; retrospectively registered trial on 4 January 2019.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
